Simin Sun

NMPA Key Laboratory For Clinical Research And Evaluation Of Innovative Drug
Jinan, 250012, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Design, Synthesis, and Anti-inflammatory Activity Evaluation for Hydrazide-Based HDAC6 Targeted Protein Degraders.

Design, Synthesis, and Anti-inflammatory Activity Evaluation for Hydrazide-Based HDAC6 Targeted Protein Degraders.

Journal: Journal of medicinal chemistry

Published: November 11, 2025

Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases.

Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases.

Journal: Journal of medicinal chemistry

Published: April 07, 2025

Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13.

Design, synthesis, and anti-cancer evaluation of the novel conjugate of gemcitabine's ProTide prodrug based on CD13.

Journal: Bioorganic chemistry

Published: January 13, 2025

Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.

Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 14, 2024

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors.

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: July 07, 2024

Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.

Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.

Journal: European journal of medicinal chemistry

Published: May 08, 2024

Discovery, Total Synthesis, and Anti-Inflammatory Evaluation of Naturally Occurring Naphthopyrone-Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors.

Discovery, Total Synthesis, and Anti-Inflammatory Evaluation of Naturally Occurring Naphthopyrone-Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors.

Journal: Angewandte Chemie (International ed. in English)

Published: March 26, 2024

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors.

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors.

Journal: Bioorganic chemistry

Published: January 02, 2024

Discovery of Novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.

Discovery of Novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis.

Journal: Journal of medicinal chemistry

Published: November 29, 2023

HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.

HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.

Journal: European journal of medicinal chemistry

Published: November 05, 2023

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.

Journal: Molecules (Basel, Switzerland)

Published: July 19, 2023

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.

Journal: Journal of medicinal chemistry

Published: September 08, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026